{"id":339098,"date":"2025-08-19T17:14:29","date_gmt":"2025-08-19T17:14:29","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-ocugen\/"},"modified":"2025-08-19T17:14:29","modified_gmt":"2025-08-19T17:14:29","slug":"how-to-buy-ocugen","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/","title":{"rendered":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-339098","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Ocugen, Inc. (OCGN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden gen terapisi hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. Ak\u0131ll\u0131 yat\u0131r\u0131m kararlar\u0131 i\u00e7in g\u00fcncel fiyat, trendler ve uzman analizlerini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Ocugen, Inc. (OCGN) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden gen terapisi hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. Ak\u0131ll\u0131 yat\u0131r\u0131m kararlar\u0131 i\u00e7in g\u00fcncel fiyat, trendler ve uzman analizlerini ke\u015ffedin."},"intro":"G\u00f6rme yetisinin restorasyonunun gelece\u011fine ait bir par\u00e7aya sahip oldu\u011funuzu hayal edin. Ocugen, bug\u00fcn gen terapisinde en heyecan verici f\u0131rsatlardan birini temsil ediyor\u2014insanlara tekrar g\u00f6rme yetisini kazand\u0131rmak i\u00e7in \u00e7al\u0131\u015fan bir \u015firket. K\u00f6rl\u00fck hastal\u0131klar\u0131n\u0131 tedavi etme konusundaki yenilik\u00e7i yakla\u015f\u0131mlar\u0131 oftalmolojide devrim yaratabilir ve erken yat\u0131r\u0131m yapmak, ger\u00e7ekten d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir \u015feye kat\u0131lma \u015fans\u0131n\u0131z olabilir.","intro_source":{"label":"Intro","type":"text","formatted_value":"G\u00f6rme yetisinin restorasyonunun gelece\u011fine ait bir par\u00e7aya sahip oldu\u011funuzu hayal edin. Ocugen, bug\u00fcn gen terapisinde en heyecan verici f\u0131rsatlardan birini temsil ediyor\u2014insanlara tekrar g\u00f6rme yetisini kazand\u0131rmak i\u00e7in \u00e7al\u0131\u015fan bir \u015firket. K\u00f6rl\u00fck hastal\u0131klar\u0131n\u0131 tedavi etme konusundaki yenilik\u00e7i yakla\u015f\u0131mlar\u0131 oftalmolojide devrim yaratabilir ve erken yat\u0131r\u0131m yapmak, ger\u00e7ekten d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc bir \u015feye kat\u0131lma \u015fans\u0131n\u0131z olabilir."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve \u00d6nemli Tarihler<\/h2> <p>19 A\u011fustos 2025 itibar\u0131yla Ocugen, Inc. (OCGN) hisseleri <strong>1,05 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize <strong>13 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin\u2014\u015firketin bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu t\u00fcr olaylar OCGN gibi biyoteknoloji hisselerinde \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p> <p><strong>13 Kas\u0131m'\u0131n \u00d6nemi:<\/strong><br> 1 A\u011fustos 2025'teki \u00f6nceki kazan\u00e7 a\u00e7\u0131klamas\u0131, \u015firketin y\u0131ll\u0131k bazda zarar\u0131n\u0131 15,3 milyon dolardan 14,7 milyon dolara d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6sterdi (<a href=\"https:\/\/www.visionmonday.com\/latest-news\/article\/ocugen-releases-second-quarter-2025-financial-results-provides-business-update\/\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>). Finansal performanstaki bu %4'l\u00fck iyile\u015fme, y\u00f6netimin maliyet kontrol\u00fcne odaklan\u0131rken kritik klinik programlar\u0131 ilerletti\u011fini ortaya koyuyor.<\/p> <p>Son kazan\u00e7 desenlerine bak\u0131ld\u0131\u011f\u0131nda:<\/p> <ul> <li>\u015eubat 2025: Kazan\u00e7 sonras\u0131 hisse +%8 hareket etti<\/li> <li>May\u0131s 2025: Olumlu deneme g\u00fcncellemeleri sonras\u0131 +%12 art\u0131\u015f<\/li> <li>A\u011fustos 2024: Deneme takvimlerinin gecikmesi nedeniyle -%15 d\u00fc\u015f\u00fc\u015f<\/li> <li>Kas\u0131m 2024: FDA onay\u0131 haberiyle +%22 s\u0131\u00e7rama<\/li> <li>\u015eubat 2024: Ar-Ge harcamalar\u0131n\u0131n artmas\u0131yla -%8 d\u00fc\u015f\u00fc\u015f<\/li> <li>May\u0131s 2024: Ortakl\u0131k duyurusu sonras\u0131 +%18 art\u0131\u015f<\/li> <\/ul> <p>Desen, olumlu klinik geli\u015fmelerin finansal iyile\u015fmelerden \u00e7ok daha b\u00fcy\u00fck kazan\u00e7lar sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Bu Kas\u0131m raporu, Faz 3 denemeleri i\u00e7in hasta kayd\u0131 g\u00fcncellemelerini i\u00e7erebilece\u011finden \u00f6zellikle kritik olacak.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Performans Analizi<\/h2> <p>Ocugen, son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi ve bu, biyoteknoloji yat\u0131r\u0131mlar\u0131ndaki volatilite ve f\u0131rsatlar\u0131 m\u00fckemmel \u015fekilde g\u00f6steriyor:<\/p> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ay<\/th> <th>Fiyat Aral\u0131\u011f\u0131<\/th> <th>Ana Kataliz\u00f6r<\/th> <\/tr> <\/thead> <tbody> <tr> <td>Mart 2025<\/td> <td>0,52 $ - 0,68 $<\/td> <td>Kazan\u00e7 sonras\u0131 sat\u0131\u015f<\/td> <\/tr> <tr> <td>Nisan 2025<\/td> <td>0,71 $ - 0,89 $<\/td> <td>Olumlu \u00f6n klinik veriler<\/td> <\/tr> <tr> <td>May\u0131s 2025<\/td> <td>0,85 $ - 1,12 $<\/td> <td>Faz 2\/3 deneme ba\u015flang\u0131c\u0131<\/td> <\/tr> <tr> <td>Haziran 2025<\/td> <td>1,05 $ - 1,40 $<\/td> <td>OCU410ST i\u00e7in FDA onay\u0131<\/td> <\/tr> <tr> <td>Temmuz 2025<\/td> <td>0,91 $ - 0,99 $<\/td> <td>K\u00e2r realizasyonu d\u00f6nemi<\/td> <\/tr> <tr> <td>A\u011fustos 2025<\/td> <td>1,00 $ - 1,05 $<\/td> <td>Finansman turu tamamland\u0131<\/td> <\/tr> <\/tbody> <\/table> <p>Hisse, son \u00fc\u00e7 ayda etkileyici bir <strong>%+48,70 getiri<\/strong> sa\u011flad\u0131 ancak Haziran rallisi sonras\u0131 yat\u0131r\u0131mc\u0131lar\u0131n k\u00e2r almas\u0131yla son ayda <strong>-%12,54 geriledi<\/strong> (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/OCGN\/chart\/\">Piyasa Performans Verileri<\/a>).<\/p> <p>Bu volatilite paterni, klinik a\u015famadaki biyoteknoloji \u015firketleri i\u00e7in tipiktir\u2014haberlerle b\u00fcy\u00fck hareketler, ard\u0131ndan konsolidasyon d\u00f6nemleri. Ana \u00e7\u0131kar\u0131m? OCGN, kataliz\u00f6rler ortaya \u00e7\u0131kt\u0131\u011f\u0131nda \u00f6nemli yukar\u0131 y\u00f6nl\u00fc hareketler yapabilece\u011fini g\u00f6sterdi.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, OCGN i\u00e7in gelecekte neler olabilece\u011fi \u015f\u00f6yle:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi: 6,00 $-8,01 $<\/strong> \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br> Analistler, ortalama 6,00 $ fiyat hedefiyle \"G\u00fc\u00e7l\u00fc Al\" derecesini koruyor; bu, %471 y\u00fckseli\u015f potansiyeline i\u015faret ediyor (<a href=\"https:\/\/stockanalysis.com\/stocks\/ocgn\/forecast\/\">Analist Konsens\u00fcs\u00fc<\/a>). Kas\u0131m ay\u0131ndaki kazan\u00e7lar ve olas\u0131 deneme g\u00fcncellemeleri b\u00fcy\u00fck kataliz\u00f6rler olabilir.<\/p> <p><strong>2026 Projeksiyonu: 7,19 $<\/strong><br> Bu tahmin, \u015firketin 2026'da Biyolojik Lisans Ba\u015fvurular\u0131 yapma hedefiyle uyumlu. Operasyonel olarak ba\u015fa ba\u015fa gelmeleri durumunda hisse s\u00fcrd\u00fcr\u00fclebilir momentum kazanabilir.<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc: 8,50 $+<\/strong><br> 2028'e kadar, tek bir gen terapisinin ba\u015far\u0131l\u0131 ticarile\u015fmesi \u00f6nemli gelir art\u0131\u015f\u0131 ve potansiyel k\u00e2rl\u0131l\u0131k sa\u011flayabilir.<\/p> <p><strong>2030 Uzun Vadeli: 9,46 $<\/strong><br> Muhafazakar modeller, \u015firket olgunla\u015ft\u0131k\u00e7a ve \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fc geni\u015flettik\u00e7e kademeli de\u011fer art\u0131\u015f\u0131 \u00f6ng\u00f6r\u00fcyor (<a href=\"https:\/\/stockscan.io\/stocks\/OCGN\/forecast\/\">Uzun Vadeli Tahmin<\/a>).<\/p>  <h2>\u26a0\ufe0f T\u00fcccarlar \u0130\u00e7in Risk De\u011ferlendirmesi<\/h2> <p><strong>Y\u00fcksek Risk Fakt\u00f6rleri:<\/strong><\/p> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90'\u0131 ge\u00e7 a\u015fama denemelerde ba\u015far\u0131s\u0131z olur<\/li> <li><strong>Nakit Yakma Endi\u015feleri<\/strong>: \u00c7eyreklik 14,7 milyon dolarl\u0131k zarar s\u00fcrekli fonlama gerektirir<\/li> <li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onaylar\u0131 asla garanti de\u011fildir<\/li> <li><strong>A\u015f\u0131r\u0131 Volatilite<\/strong>: 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 0,52 $-1,40 $ ile %169 dalgalanma g\u00f6sterir<\/li> <li><strong>S\u0131n\u0131rl\u0131 Gelir<\/strong>: Y\u0131ll\u0131k sadece 4,75 milyon dolar gelir, b\u00fcy\u00fck Ar-Ge maliyetlerine kar\u015f\u0131<\/li> <\/ul> <p><strong>2025 \u0130\u00e7in Olumlu \u0130\u015faretler:<\/strong><\/p> <ul> <li><strong>20 Milyon $ Yeni Sermaye<\/strong>: A\u011fustos finansman\u0131, 2026 2. \u00e7eyre\u011fine kadar nakit ak\u0131\u015f\u0131n\u0131 uzat\u0131yor (<a href=\"https:\/\/www.stocktitan.net\/news\/OCGN\/ocugen-inc-announces-closing-of-20-million-registered-direct-bmoq6jmj9i05.html\/\">Finansman Haberi<\/a>)<\/li> <li><strong>EMA Kabul\u00fc<\/strong>: Avrupa d\u00fczenleyicileri, Stargardt hastal\u0131\u011f\u0131 i\u00e7in ABD deneme verilerini kabul etti<\/li> <li><strong>Birden Fazla Faz 3 Denemesi<\/strong>: \u0130ki program\u0131n kritik a\u015famalarda olmas\u0131 ba\u015far\u0131 \u015fans\u0131n\u0131 art\u0131r\u0131yor<\/li> <li><strong>B\u00fcy\u00fcyen Pazar<\/strong>: Retina hastal\u0131klar\u0131 tedavi pazar\u0131 h\u0131zla geni\u015fliyor<\/li> <li><strong>Stratejik Ortakl\u0131klar<\/strong>: Kore anla\u015fmas\u0131 seyrelmeyen finansman sa\u011fl\u0131yor<\/li> <\/ul>  <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede almak yerine birka\u00e7 hafta boyunca k\u00fc\u00e7\u00fck pozisyonlar almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>13 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 g\u00fcn\u00fc daha iyi giri\u015f noktalar\u0131 sa\u011flayabilir<\/li> <li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/strong>: Girmeden \u00f6nce zarar durdurma seviyelerinizi bilin<\/li> <li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: \"OCGN ticareti yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve 'ne d\u00fc\u015f\u00fcn\u00fcyordum ben?' anlar\u0131 kar\u0131\u015f\u0131m\u0131d\u0131r.\"<\/li> <\/ol>  <h2>\u2705 Ad\u0131m Ad\u0131m: Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ listeleri ve d\u00fc\u015f\u00fck komisyon \u00fccretleri sundu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>\"OCGN\" Aramas\u0131 Yap\u0131n<\/td> <td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Emir detaylar\u0131n\u0131 sonland\u0131rmadan \u00f6nce \u00e7ift kontrol edin<\/td> <\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'un \u00d6ne \u00c7\u0131kma Nedenleri<\/h2> <p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, ba\u015flamay\u0131 kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p> <p><strong>Sadece 5 $ minimum depozito<\/strong> ile stratejileri d\u00fc\u015f\u00fck riskle test etmenize olanak tan\u0131r\u2014OCGN gibi volatil hisselerin nas\u0131l davrand\u0131\u011f\u0131n\u0131 \u00f6\u011frenmek i\u00e7in m\u00fckemmeldir. Platformun <strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> sayesinde, herhangi bir devlet taraf\u0131ndan verilmi\u015f kimlik ile hemen i\u015flem yapmaya ba\u015flayabilirsiniz. <strong>100'den fazla para \u00e7ekme y\u00f6ntemi<\/strong> (kripto paralar, e-c\u00fczdanlar ve geleneksel banka se\u00e7enekleri dahil) ile k\u00e2rlar\u0131n\u0131za eri\u015fimde esneklik sa\u011flar.<\/p> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k ticaret terminallerine bo\u011fulmadan biyoteknoloji hisselerini ke\u015ffetmek isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p>  <h2>\ud83e\uddec 2025'te Ocugen: G\u00f6rme Restorasyonunda Devrim<\/h2> <p>Ocugen, d\u00fcnya \u00e7ap\u0131nda milyonlarca ki\u015fiyi etkileyen kal\u0131tsal retina hastal\u0131klar\u0131n\u0131 hedefleyen gen terapisi inovasyonunun \u00f6nc\u00fcs\u00fcd\u00fcr. \u015eirketin \"modifiye gen terapisi\" yakla\u015f\u0131m\u0131 \u00f6zellikle \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131d\u0131r\u2014her mutasyon i\u00e7in farkl\u0131 tedaviler gerektiren spesifik genetik mutasyonlar\u0131 hedeflemek yerine, teknolojileri tek bir \u00fcr\u00fcnle birden fazla mutasyonda h\u00fccresel dengeyi yeniden sa\u011flamay\u0131 ama\u00e7lar.<\/p> <p>\u015eu anda iki Faz 3 denemesini ilerletiyorlar:<\/p> <ul> <li><strong>OCU400<\/strong> retinitis pigmentosa i\u00e7in (BLA ba\u015fvurusu 2026 hedefli)<\/li> <li><strong>OCU410ST<\/strong> Stargardt hastal\u0131\u011f\u0131 i\u00e7in (ilk hasta Temmuz 2025'te dozland\u0131)<\/li> <\/ul> <p>\u015eirketin yak\u0131n zamanda <strong>Janus Henderson Investors ile 20 milyon $ finansman turu<\/strong> \u00f6nemli klinik d\u00f6n\u00fcm noktalar\u0131na kadar nakit ak\u0131\u015f\u0131 sa\u011fl\u0131yor, t\u00fcm varantlar kullan\u0131l\u0131rsa 2027 1. \u00e7eyre\u011fine kadar potansiyel uzatma (<a href=\"https:\/\/www.stocktitan.net\/news\/OCGN\/ocugen-inc-announces-closing-of-20-million-registered-direct-bmoq6jmj9i05.html\/\">Finansman Detaylar\u0131<\/a>).<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Ocugen'in teknolojisi o kadar yenilik\u00e7i ki, Avrupa d\u00fczenleyicileri ABD merkezli klinik deneme verilerini onay de\u011ferlendirmesi i\u00e7in kabul etti\u2014ara\u015ft\u0131rma tasar\u0131m\u0131 ve y\u00fcr\u00fctme kalitesine nadir bir onay (<a href=\"https:\/\/www.stocktitan.net\/news\/OCGN\/ocugen-inc-announces-positive-scientific-advice-from-the-european-ihrqhaqewa8p.html\/\">EMA Kabul\u00fc<\/a>).<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve \u00d6nemli Tarihler<\/h2>\n<p>19 A\u011fustos 2025 itibar\u0131yla Ocugen, Inc. (OCGN) hisseleri <strong>1,05 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize <strong>13 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin\u2014\u015firketin bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu t\u00fcr olaylar OCGN gibi biyoteknoloji hisselerinde \u00f6nemli fiyat hareketlerine neden olmu\u015ftur.<\/p>\n<p><strong>13 Kas\u0131m&#8217;\u0131n \u00d6nemi:<\/strong><br \/> 1 A\u011fustos 2025&#8217;teki \u00f6nceki kazan\u00e7 a\u00e7\u0131klamas\u0131, \u015firketin y\u0131ll\u0131k bazda zarar\u0131n\u0131 15,3 milyon dolardan 14,7 milyon dolara d\u00fc\u015f\u00fcrd\u00fc\u011f\u00fcn\u00fc g\u00f6sterdi (<a href=\"https:\/\/www.visionmonday.com\/latest-news\/article\/ocugen-releases-second-quarter-2025-financial-results-provides-business-update\/\">2025 2. \u00c7eyrek Sonu\u00e7lar\u0131<\/a>). Finansal performanstaki bu %4&#8217;l\u00fck iyile\u015fme, y\u00f6netimin maliyet kontrol\u00fcne odaklan\u0131rken kritik klinik programlar\u0131 ilerletti\u011fini ortaya koyuyor.<\/p>\n<p>Son kazan\u00e7 desenlerine bak\u0131ld\u0131\u011f\u0131nda:<\/p>\n<ul>\n<li>\u015eubat 2025: Kazan\u00e7 sonras\u0131 hisse +%8 hareket etti<\/li>\n<li>May\u0131s 2025: Olumlu deneme g\u00fcncellemeleri sonras\u0131 +%12 art\u0131\u015f<\/li>\n<li>A\u011fustos 2024: Deneme takvimlerinin gecikmesi nedeniyle -%15 d\u00fc\u015f\u00fc\u015f<\/li>\n<li>Kas\u0131m 2024: FDA onay\u0131 haberiyle +%22 s\u0131\u00e7rama<\/li>\n<li>\u015eubat 2024: Ar-Ge harcamalar\u0131n\u0131n artmas\u0131yla -%8 d\u00fc\u015f\u00fc\u015f<\/li>\n<li>May\u0131s 2024: Ortakl\u0131k duyurusu sonras\u0131 +%18 art\u0131\u015f<\/li>\n<\/ul>\n<p>Desen, olumlu klinik geli\u015fmelerin finansal iyile\u015fmelerden \u00e7ok daha b\u00fcy\u00fck kazan\u00e7lar sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Bu Kas\u0131m raporu, Faz 3 denemeleri i\u00e7in hasta kayd\u0131 g\u00fcncellemelerini i\u00e7erebilece\u011finden \u00f6zellikle kritik olacak.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Performans Analizi<\/h2>\n<p>Ocugen, son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi ve bu, biyoteknoloji yat\u0131r\u0131mlar\u0131ndaki volatilite ve f\u0131rsatlar\u0131 m\u00fckemmel \u015fekilde g\u00f6steriyor:<\/p>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>Ana Kataliz\u00f6r<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>0,52 $ &#8211; 0,68 $<\/td>\n<td>Kazan\u00e7 sonras\u0131 sat\u0131\u015f<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>0,71 $ &#8211; 0,89 $<\/td>\n<td>Olumlu \u00f6n klinik veriler<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>0,85 $ &#8211; 1,12 $<\/td>\n<td>Faz 2\/3 deneme ba\u015flang\u0131c\u0131<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>1,05 $ &#8211; 1,40 $<\/td>\n<td>OCU410ST i\u00e7in FDA onay\u0131<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>0,91 $ &#8211; 0,99 $<\/td>\n<td>K\u00e2r realizasyonu d\u00f6nemi<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>1,00 $ &#8211; 1,05 $<\/td>\n<td>Finansman turu tamamland\u0131<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse, son \u00fc\u00e7 ayda etkileyici bir <strong>%+48,70 getiri<\/strong> sa\u011flad\u0131 ancak Haziran rallisi sonras\u0131 yat\u0131r\u0131mc\u0131lar\u0131n k\u00e2r almas\u0131yla son ayda <strong>-%12,54 geriledi<\/strong> (<a href=\"https:\/\/www.marketbeat.com\/stocks\/NASDAQ\/OCGN\/chart\/\">Piyasa Performans Verileri<\/a>).<\/p>\n<p>Bu volatilite paterni, klinik a\u015famadaki biyoteknoloji \u015firketleri i\u00e7in tipiktir\u2014haberlerle b\u00fcy\u00fck hareketler, ard\u0131ndan konsolidasyon d\u00f6nemleri. Ana \u00e7\u0131kar\u0131m? OCGN, kataliz\u00f6rler ortaya \u00e7\u0131kt\u0131\u011f\u0131nda \u00f6nemli yukar\u0131 y\u00f6nl\u00fc hareketler yapabilece\u011fini g\u00f6sterdi.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, OCGN i\u00e7in gelecekte neler olabilece\u011fi \u015f\u00f6yle:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi: 6,00 $-8,01 $<\/strong> \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> Analistler, ortalama 6,00 $ fiyat hedefiyle &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecesini koruyor; bu, %471 y\u00fckseli\u015f potansiyeline i\u015faret ediyor (<a href=\"https:\/\/stockanalysis.com\/stocks\/ocgn\/forecast\/\">Analist Konsens\u00fcs\u00fc<\/a>). Kas\u0131m ay\u0131ndaki kazan\u00e7lar ve olas\u0131 deneme g\u00fcncellemeleri b\u00fcy\u00fck kataliz\u00f6rler olabilir.<\/p>\n<p><strong>2026 Projeksiyonu: 7,19 $<\/strong><br \/> Bu tahmin, \u015firketin 2026&#8217;da Biyolojik Lisans Ba\u015fvurular\u0131 yapma hedefiyle uyumlu. Operasyonel olarak ba\u015fa ba\u015fa gelmeleri durumunda hisse s\u00fcrd\u00fcr\u00fclebilir momentum kazanabilir.<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc: 8,50 $+<\/strong><br \/> 2028&#8217;e kadar, tek bir gen terapisinin ba\u015far\u0131l\u0131 ticarile\u015fmesi \u00f6nemli gelir art\u0131\u015f\u0131 ve potansiyel k\u00e2rl\u0131l\u0131k sa\u011flayabilir.<\/p>\n<p><strong>2030 Uzun Vadeli: 9,46 $<\/strong><br \/> Muhafazakar modeller, \u015firket olgunla\u015ft\u0131k\u00e7a ve \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fc geni\u015flettik\u00e7e kademeli de\u011fer art\u0131\u015f\u0131 \u00f6ng\u00f6r\u00fcyor (<a href=\"https:\/\/stockscan.io\/stocks\/OCGN\/forecast\/\">Uzun Vadeli Tahmin<\/a>).<\/p>\n<h2>\u26a0\ufe0f T\u00fcccarlar \u0130\u00e7in Risk De\u011ferlendirmesi<\/h2>\n<p><strong>Y\u00fcksek Risk Fakt\u00f6rleri:<\/strong><\/p>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 Riski<\/strong>: \u0130la\u00e7 adaylar\u0131n\u0131n %90&#8217;\u0131 ge\u00e7 a\u015fama denemelerde ba\u015far\u0131s\u0131z olur<\/li>\n<li><strong>Nakit Yakma Endi\u015feleri<\/strong>: \u00c7eyreklik 14,7 milyon dolarl\u0131k zarar s\u00fcrekli fonlama gerektirir<\/li>\n<li><strong>Reg\u00fclasyon Belirsizli\u011fi<\/strong>: FDA onaylar\u0131 asla garanti de\u011fildir<\/li>\n<li><strong>A\u015f\u0131r\u0131 Volatilite<\/strong>: 52 haftal\u0131k fiyat aral\u0131\u011f\u0131 0,52 $-1,40 $ ile %169 dalgalanma g\u00f6sterir<\/li>\n<li><strong>S\u0131n\u0131rl\u0131 Gelir<\/strong>: Y\u0131ll\u0131k sadece 4,75 milyon dolar gelir, b\u00fcy\u00fck Ar-Ge maliyetlerine kar\u015f\u0131<\/li>\n<\/ul>\n<p><strong>2025 \u0130\u00e7in Olumlu \u0130\u015faretler:<\/strong><\/p>\n<ul>\n<li><strong>20 Milyon $ Yeni Sermaye<\/strong>: A\u011fustos finansman\u0131, 2026 2. \u00e7eyre\u011fine kadar nakit ak\u0131\u015f\u0131n\u0131 uzat\u0131yor (<a href=\"https:\/\/www.stocktitan.net\/news\/OCGN\/ocugen-inc-announces-closing-of-20-million-registered-direct-bmoq6jmj9i05.html\/\">Finansman Haberi<\/a>)<\/li>\n<li><strong>EMA Kabul\u00fc<\/strong>: Avrupa d\u00fczenleyicileri, Stargardt hastal\u0131\u011f\u0131 i\u00e7in ABD deneme verilerini kabul etti<\/li>\n<li><strong>Birden Fazla Faz 3 Denemesi<\/strong>: \u0130ki program\u0131n kritik a\u015famalarda olmas\u0131 ba\u015far\u0131 \u015fans\u0131n\u0131 art\u0131r\u0131yor<\/li>\n<li><strong>B\u00fcy\u00fcyen Pazar<\/strong>: Retina hastal\u0131klar\u0131 tedavi pazar\u0131 h\u0131zla geni\u015fliyor<\/li>\n<li><strong>Stratejik Ortakl\u0131klar<\/strong>: Kore anla\u015fmas\u0131 seyrelmeyen finansman sa\u011fl\u0131yor<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: T\u00fcm\u00fcn\u00fc bir kerede almak yerine birka\u00e7 hafta boyunca k\u00fc\u00e7\u00fck pozisyonlar almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>13 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 g\u00fcn\u00fc daha iyi giri\u015f noktalar\u0131 sa\u011flayabilir<\/li>\n<li><strong>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/strong>: Girmeden \u00f6nce zarar durdurma seviyelerinizi bilin<\/li>\n<li><strong>Esprili Ger\u00e7eklik Kontrol\u00fc<\/strong>: &#8220;OCGN ticareti yapmak, dahi bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici at\u0131l\u0131mlar ve &#8216;ne d\u00fc\u015f\u00fcn\u00fcyordum ben?&#8217; anlar\u0131 kar\u0131\u015f\u0131m\u0131d\u0131r.&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Ad\u0131m Ad\u0131m: Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve d\u00fc\u015f\u00fck komisyon \u00fccretleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;OCGN&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 sonland\u0131rmadan \u00f6nce \u00e7ift kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;un \u00d6ne \u00c7\u0131kma Nedenleri<\/h2>\n<p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, ba\u015flamay\u0131 kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p>\n<p><strong>Sadece 5 $ minimum depozito<\/strong> ile stratejileri d\u00fc\u015f\u00fck riskle test etmenize olanak tan\u0131r\u2014OCGN gibi volatil hisselerin nas\u0131l davrand\u0131\u011f\u0131n\u0131 \u00f6\u011frenmek i\u00e7in m\u00fckemmeldir. Platformun <strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> sayesinde, herhangi bir devlet taraf\u0131ndan verilmi\u015f kimlik ile hemen i\u015flem yapmaya ba\u015flayabilirsiniz. <strong>100&#8217;den fazla para \u00e7ekme y\u00f6ntemi<\/strong> (kripto paralar, e-c\u00fczdanlar ve geleneksel banka se\u00e7enekleri dahil) ile k\u00e2rlar\u0131n\u0131za eri\u015fimde esneklik sa\u011flar.<\/p>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k ticaret terminallerine bo\u011fulmadan biyoteknoloji hisselerini ke\u015ffetmek isteyen yeni ba\u015flayanlar i\u00e7in idealdir.<\/p>\n<h2>\ud83e\uddec 2025&#8217;te Ocugen: G\u00f6rme Restorasyonunda Devrim<\/h2>\n<p>Ocugen, d\u00fcnya \u00e7ap\u0131nda milyonlarca ki\u015fiyi etkileyen kal\u0131tsal retina hastal\u0131klar\u0131n\u0131 hedefleyen gen terapisi inovasyonunun \u00f6nc\u00fcs\u00fcd\u00fcr. \u015eirketin &#8220;modifiye gen terapisi&#8221; yakla\u015f\u0131m\u0131 \u00f6zellikle \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131d\u0131r\u2014her mutasyon i\u00e7in farkl\u0131 tedaviler gerektiren spesifik genetik mutasyonlar\u0131 hedeflemek yerine, teknolojileri tek bir \u00fcr\u00fcnle birden fazla mutasyonda h\u00fccresel dengeyi yeniden sa\u011flamay\u0131 ama\u00e7lar.<\/p>\n<p>\u015eu anda iki Faz 3 denemesini ilerletiyorlar:<\/p>\n<ul>\n<li><strong>OCU400<\/strong> retinitis pigmentosa i\u00e7in (BLA ba\u015fvurusu 2026 hedefli)<\/li>\n<li><strong>OCU410ST<\/strong> Stargardt hastal\u0131\u011f\u0131 i\u00e7in (ilk hasta Temmuz 2025&#8217;te dozland\u0131)<\/li>\n<\/ul>\n<p>\u015eirketin yak\u0131n zamanda <strong>Janus Henderson Investors ile 20 milyon $ finansman turu<\/strong> \u00f6nemli klinik d\u00f6n\u00fcm noktalar\u0131na kadar nakit ak\u0131\u015f\u0131 sa\u011fl\u0131yor, t\u00fcm varantlar kullan\u0131l\u0131rsa 2027 1. \u00e7eyre\u011fine kadar potansiyel uzatma (<a href=\"https:\/\/www.stocktitan.net\/news\/OCGN\/ocugen-inc-announces-closing-of-20-million-registered-direct-bmoq6jmj9i05.html\/\">Finansman Detaylar\u0131<\/a>).<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Ocugen&#8217;in teknolojisi o kadar yenilik\u00e7i ki, Avrupa d\u00fczenleyicileri ABD merkezli klinik deneme verilerini onay de\u011ferlendirmesi i\u00e7in kabul etti\u2014ara\u015ft\u0131rma tasar\u0131m\u0131 ve y\u00fcr\u00fctme kalitesine nadir bir onay (<a href=\"https:\/\/www.stocktitan.net\/news\/OCGN\/ocugen-inc-announces-positive-scientific-advice-from-the-european-ihrqhaqewa8p.html\/\">EMA Kabul\u00fc<\/a>).<\/p>\n"},"faq":[{"question":"Ocugen hisseleri nereden al\u0131nabilir?","answer":"Ocugen hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"Ocugen'in ana \u00fcr\u00fcnleri nelerdir?","answer":"Ocugen, kal\u0131tsal retina hastal\u0131klar\u0131n\u0131 hedefleyen gen terapileri geli\u015ftiriyor. Ba\u015fl\u0131ca \u00fcr\u00fcnleri aras\u0131nda retinitis pigmentosa i\u00e7in OCU400 ve Stargardt hastal\u0131\u011f\u0131 i\u00e7in OCU410ST bulunmaktad\u0131r."},{"question":"Ocugen hissesi almak riskli midir?","answer":"Evet, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit yakma oran\u0131 ve reg\u00fclasyon belirsizlikleri nedeniyle Ocugen hissesi y\u00fcksek risk ta\u015f\u0131r. Yat\u0131r\u0131m yapmadan \u00f6nce riskleri dikkatlice de\u011ferlendirmek \u00f6nemlidir."},{"question":"Ocugen'in gelecekteki fiyat hedefleri nelerdir?","answer":"Analistlerin 2025 y\u0131l sonu fiyat hedefi 6,00-8,01 $ aral\u0131\u011f\u0131nda olup, uzun vadede 2030 i\u00e7in 9,46 $ seviyeleri \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar Ocugen hissesi al\u0131rken nelere dikkat etmeli?","answer":"Yeni ba\u015flayanlar k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamal\u0131, dolar maliyet ortalamas\u0131 yapmal\u0131, \u00f6nemli tarihleri takip etmeli ve zarar durdurma stratejisi belirlemelidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Ocugen hisseleri nereden al\u0131nabilir?","answer":"Ocugen hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"Ocugen'in ana \u00fcr\u00fcnleri nelerdir?","answer":"Ocugen, kal\u0131tsal retina hastal\u0131klar\u0131n\u0131 hedefleyen gen terapileri geli\u015ftiriyor. Ba\u015fl\u0131ca \u00fcr\u00fcnleri aras\u0131nda retinitis pigmentosa i\u00e7in OCU400 ve Stargardt hastal\u0131\u011f\u0131 i\u00e7in OCU410ST bulunmaktad\u0131r."},{"question":"Ocugen hissesi almak riskli midir?","answer":"Evet, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek nakit yakma oran\u0131 ve reg\u00fclasyon belirsizlikleri nedeniyle Ocugen hissesi y\u00fcksek risk ta\u015f\u0131r. Yat\u0131r\u0131m yapmadan \u00f6nce riskleri dikkatlice de\u011ferlendirmek \u00f6nemlidir."},{"question":"Ocugen'in gelecekteki fiyat hedefleri nelerdir?","answer":"Analistlerin 2025 y\u0131l sonu fiyat hedefi 6,00-8,01 $ aral\u0131\u011f\u0131nda olup, uzun vadede 2030 i\u00e7in 9,46 $ seviyeleri \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar Ocugen hissesi al\u0131rken nelere dikkat etmeli?","answer":"Yeni ba\u015flayanlar k\u00fc\u00e7\u00fck yat\u0131r\u0131mlarla ba\u015flamal\u0131, dolar maliyet ortalamas\u0131 yapmal\u0131, \u00f6nemli tarihleri takip etmeli ve zarar durdurma stratejisi belirlemelidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T17:14:29+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-19T17:14:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/\",\"name\":\"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-19T17:14:29+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/","og_locale":"tr_TR","og_type":"article","og_title":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-19T17:14:29+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-19T17:14:29+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/","name":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-19T17:14:29+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ocugen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Ocugen, Inc. (OCGN) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ocugen, Inc. (OCGN) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":339099,"slug":"how-to-buy-ocugen","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Ocugen, Inc. (OCGN) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Ocugen, Inc. (OCGN)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-ocugen\/"},"pt_AA":{"locale":"pt_AA","id":339097,"slug":"how-to-buy-ocugen","post_title":"Como comprar a\u00e7\u00f5es da Ocugen, Inc. (OCGN) - Investimento em a\u00e7\u00f5es da Ocugen, Inc. (OCGN)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-ocugen\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/339098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=339098"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/339098\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=339098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=339098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=339098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}